Constellation Pharmaceuticals’ $224.3 Million Common Stock Offering


Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the offering. Wilmer Cutler Pickering Hale and Dorr advised Constellation Pharmaceuticals.

Constellation Pharmaceuticals completed its $224.3 million offering of common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “CNST.”

J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC, RBC Capital Markets, LLC, and SunTrust Robinson Humphrey, Inc. acted as underwriters in this offering.

Based in Cambridge, Massachusetts, Constellation is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. (Picture) and associates Cameron C. Lewis and Johnathan M. Nixon. Partner David R. Bauer and associate Christopher C. Woller provided intellectual property and technology advice. Partner William A. Curran and associate Alexander J. Hendin provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; William Curran – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Alexander Hendin – Davis Polk & Wardwell; Cameron Lewis – Davis Polk & Wardwell; Johnathan Nixon – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company; J.P. Morgan Securities LLC; Jefferies; RBC Capital Markets; SunTrust Robinson Humphrey, Inc.;

Author: Ambrogio Visconti